文献速递重症综合管理与镇静镇痛

衰弱与体外膜肺氧合后结局:一项基于两国登记的队列研究

Frailty and outcomes after extracorporeal membrane oxygenation: a binational registry-based cohort study.
PubMed 文献 · Crit Care · 2025-12-27
一句话结论在116个ICU接受ECMO的成人中,CFS≥5的衰弱与1年死亡率无显著关联(校正风险差+0.27%,95%CI -6.65%至+7.19%)。

这项回顾性队列研究基于澳大利亚和新西兰重症监护学会成人患者数据库,纳入2018至2024年间116个ICU中接受ECMO的成人(≥16岁)共2084例,用临床衰弱量表(CFS)评估衰弱(CFS≥5为衰弱)。主要终点为1年死亡率,采用g-computation校正分析。结果显示,无衰弱患者校正1年死亡率为41.9%(760/1830),衰弱患者为42.1%(113/254),校正风险差+0.27%(95%CI -6.65%至+7.19%),亚组和敏感性分析结果一致。结论认为衰弱与ECMO患者短期或长期死亡率无关,可能反映ECMO候选资格的选择模式,需更多研究验证。

要点

  • 在116个ICU接受ECMO的成人中,衰弱(CFS≥5)患病率为12.2%(254/2084)。
  • 校正1年死亡率:无衰弱组41.9%(760/1830) vs 衰弱组42.1%(113/254),校正风险差+0.27%(95%CI -6.65%至+7.19%),无显著差异。
  • 亚组分析中主要诊断组风险差:心脏内科-7.87%、心脏外科+3.70%、心脏骤停-1.66%、呼吸+10.02%、移植+2.19%、其他-0.58%,结果一致。
  • 作者结论:衰弱与ECMO患者短期或长期死亡率无关,可能反映ECMO患者选择模式。
  • 作者指出需更多研究探究该关系并验证这些发现。

适用人群与场景

  • 澳大利亚和新西兰116个ICU中2018至2024年接受ECMO的成人(≥16岁),数据来自澳大利亚和新西兰重症监护学会成人患者数据库。

诊断标准与关键阈值

  • 衰弱评估采用临床衰弱量表(CFS),CFS≥5定义为衰弱。

研究设计与关键结果

  • 研究类型:回顾性队列研究,纳入116个ICU中接受ECMO的成人2084例(中位年龄51.3岁,IQR 38.9–61.3,男性64.2%)。
  • 衰弱(CFS≥5)者254例(12.2%)。
  • 主要终点1年死亡率:无衰弱组校正死亡率41.9%(760/1830),衰弱组42.1%(113/254),校正风险差+0.27%(95%CI -6.65%至+7.19%)。
  • 亚组分析主要诊断组风险差:心脏内科-7.87%、心脏外科+3.70%、心脏骤停-1.66%、呼吸+10.02%、移植+2.19%、其他-0.58%。
  • 敏感性分析和亚组分析结果一致。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为衰弱与ECMO患者短期或长期死亡率无关,可能反映ECMO患者选择模式;作者指出需更多研究探究该关系并验证这些发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Frailty predicts adverse outcomes in critical illness, but its prognostic value in patients receiving extracorporeal membrane oxygenation (ECMO) remains unclear. METHODS: In this retrospective cohort study across 116 intensive care units (ICUs), we analysed data from the Australia and New Zealand Intensive Care Society Adult Patient Database on adults (≥ 16 years) who received ECMO between 2018 and 2024. Frailty was assessed using the Clinical Frailty Scale (CFS), and we defined patients as being frail if they had a CFS of ≥ 5. The primary outcome was one-year mortality, which we assessed using g-computation. We further analysed the association between frailty and death among several subgroups, including age, sex, and primary ICU admission diagnostic group (cardiac medical, cardiac surgical, cardiac arrest, respiratory, transplant, and others). Secondary outcomes included in-hospital and ICU mortality, lengths of hospital and ICU stay, delirium, and pressure injuries. RESULTS: We included 2,084 patients (51.3 years [IQR: 38.9–61.3], 64.2% male). Frailty was present in 254 (12.2%) patients. The adjusted one-year mortality was 41.9% (760/1830) in patients without frailty and 42.1% (113/254) in patients with frailty (adjusted risk difference: +0.27%, 95%-CI: -6.65% to +7.19%). These results were consistent across sensitivity and subgroup analyses, particularly amongst principal diagnostic groups (cardiac medical: -7.87%, cardiac surgical: + 3.70%, cardiac arrest: -1.66%, respiratory: + 10.02%, transplant: + 2.19%, others: -0.58%). CONCLUSIONS: Frailty was not associated with short or long-term mortality among patients who received ECMO. This may reflect patterns in patient eligibility for ECMO. More studies are required to investigate this relationship and validate these findings.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Ling RR, Subramaniam A, Pilcher D, et al. Frailty and outcomes after extracorporeal membrane oxygenation: a binational registry-based cohort study. Crit Care. 2025. PMID: 41456011. doi:10.1186/s13054-025-05801-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。